Table 2. Association between treatment type and mortality.
| Covariates | All-cause mortality | Lung cancer-specific mortality | |||
|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||
| Treatment group | |||||
| PDT* | 1.03 | 0.73–1.45 | 1.04 | 0.71–1.51 | |
| Non-PDT ablation** | 1.22 | 1.13–1.33 | 1.10 | 1.01–1.20 | |
| Radiation + chemo (reference) | – | – | – | – | |
| Age at diagnosis | 1.01 | 1.01–1.04 | 1.00 | 1.00–1.01 | |
| Race and ethnicity | |||||
| White | 1.13 | 1.09–1.15 | 1.04 | 1.01–1.07 | |
| Other (reference) | – | – | – | – | |
| Marital status | |||||
| Married | 0.91 | 0.89–0.93 | 1.00 | 0.98–1.03 | |
| Other (reference) | – | – | – | – | |
| Gender | |||||
| Male | 1.28 | 1.26–1.31 | 1.03 | 1.01–1.05 | |
| Female (reference) | – | – | – | – | |
| Geographic region | |||||
| Metro | 0.94 | 0.92–0.97 | 0.99 | 0.97–1.02 | |
| Non-metro (reference) | – | – | – | – | |
| Commodity score | |||||
| Comorbidity ≥1 | 1.19 | 1.17–1.22 | 0.99 | 0.97–1.01 | |
| Zero comorbidity (reference) | – | – | – | – | |
| Stage | |||||
| Stage III | 0.64 | 0.62–0.65 | 0.90 | 0.88–0.92 | |
| Stage IV (reference) | – | – | – | – | |
*, PDT group includes PDT + radiation ± chemotherapy; **, non-PDT ablation group includes non-PDT ablation + radiation ± chemotherapy. PDT, photodynamic therapy.